Inhibition of Extrinsic Pathway Inhibitor Shortens the Coagulation Time of Normal Plasma and of Hemophilia Plasma

Summary

An increasing amount of evidence suggests that coagulation factors VIII and IX play a role not only in the intrinsic but also in the extrinsic pathway of coagulation. In this context the influence of the Extrinsic Pathway Inhibitor (EPI) on the coagulation time of hemophilia plasma lacking FVIII or FIX has been investigated. The coagulation time was measured in a dilute thromboplastin assay. Addition of recombinant EPI (rEPI) prolonged the coagulation time of normal plasma while the addition of an inhibitory antibody against EPI shortened the coagulation time. At low concentrations of thromboplastin the coagulation time of hemophilia plasma was prolonged and at all dilutions of thromboplastin, addition of anti-EPI IgG normalized the coagulation time of a hemophilia plasma. Analysis of 10 individual donor plasma samples and 8 individual hemophilia samples showed that addition of anti-EPI IgG shortened the coagulation time more in hemophilia plasma than in normal plasma. This illustrates the importance of a powerful extrinsic FVII dependent pathway to achieve hemostasis in the case of FVIII or FIX deficiency (hemophilia A and B).

• References

• 1 Rapaport SI. Inhibition of factor Vila/tissue factor-induced blood coagulation: With particular emphasis upon a factor Xa dependent inhibition mechanism. Blood 1989; 73: 359-65
• 2 Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze JP. Cloning and characterization of a cDNA coding for the lipoprotein associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988; 263: 6001-4
• 3 Warn-Cramer BJ, Rao LVM, Maki SL, Rapaport SI. Modification of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa tissue factor. Thromb Haemostas 1988; 6: 453-6
• 4 Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factors Xa. Blood 1988; 71: 335-43
• 5 Novotny WF, Girard TJ, Miletich JP, Broze GJ. Purification and characterization of the lipoprotein associated coagulation inhibitor from human plasma. J Biol Chem 1989; 264: 18832-7
• 6 Sandset PM, Abildgaard U, Pettersen M. A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res 1987; 47: 389-400
• 7 Bajaj MS, Rana SV, Wysolmerski RB, Bajaj SP. Inhibitor of the factor VIIa-tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease. J Clin Invest 1987; 79: 1874-8
• 8 Broze GJ, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990; 29: 7539-46
• 9 Day KC, Hoffman LC, Palmier MO, Kretzmer KK, Huang MD, Pyla EY, Spokas E, Broze GJ, Warren TG, Wun TC. Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit. Blood 1990; 78: 1538-45
• 10 Lindahl AK, Abildgaard U, Larsen ML, Aamordt LM, Nordfang O, Beck TC. Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin induced coagulation. Thromb Res 1991 in press
• 11 Biggs R, Nossel HL. Tissue extract and the contact reaction in blood coagulation. Thromb Diath Haemorrh 1961; 6: 1-14
• 12 Pedersen AH, Nordfang O, Norris F, Wiberg FC, Christensen PM, Moeller KB, Meidal-Pedersen J, Beck TC, Norris K, Hedner U, Kisiel W. Recombinant human extrinsic pathway inhibitor. J Biol Chem 1990; 265: 16786-93
• 13 Kasper CK, Aledort LM, Counts RB, Edson JR, Fratanti IJ, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, Hampton JW, McMillan CV, Pool JG, Shapiro SS, Shalman NR, Van Eys J. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-72
• 14 Nordfang O, Nielsen LS, Jacobsen PB. Purification and cloning of extrinsic pathway inhibitor from HeLa cells. Biotechnology of Plasma Proteins 1990 98 (Abstr)
• 15 Hedner U. Factor VIIa in the treatment of haemophilia. Blood Coagulation and Fibrinolysis 1990; 1: 307-17
• 16 Österud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII. Proc Natl Acad Sci USA 1977; 74: 5260-4
• 17 Komiyama Y, Pedersen A, Kisiel W. Proteolytic activation of human factors IX and X by recombinant human Factor VIIa. Biochemistry 1990; 29: 9418-25
• 18 Nordfang O. Coagulation factor VIII: Studies of its subunits. Eur J Haematol 1989; 4 3. Suppl 49 1-28
• 19 Hedner U. Schulman S, Alberts KA, Blombôck M, Johnsson H, Glazer S, Pingel K. Successful use of rFVIIa in a patient with severe hemophilia A subjected to synovectomy. Lancet 1988; ii: 1193
• 20 Macik GB, Hohneker J, Roberts H, Griffin AM. The use of recombinant activated factor VII for treatment of a retropharyngeal haemorrhage in a hemophilic patient with a high titer inhibitor. Am J Hematol 1989; 32: 232-4
• 21 Repke D, Gemmell CH, Guha A, Turitto VT, Broze GJ, Nemerson Y. Hemophilia as a defect of the tissue factor pathway of blood coagulation. Proc Natl Acad Sci USA 1990; 87: 7623-7
• 22 Wun TC, Huang MD, Kretzmer KK, Palmier MO, Day KC, Bulock JW, Fok KF, Broze GJ. Immunoaffinity purification and characterization of lipoprotein associated coagulation inhibitors from HepG2 hepatoma, Chang liver and SK hepatoma cells. J Biol Chem 1990; 265: 16096-101